Treatment regimen | SLE without prior severe organ involvement (n=24) | SLE with prior severe organ involvement (n=49) | P value |
GC dosage (mg/day)* | 0.00(0.00, 0.00) | 0.00(0.00, 0.00) | N/A |
HCQ | 10 (41.7) | 26 (53.1) | 0.46 |
Tac | 5 (20.8) | 20 (40.8) | 0.12 |
CyA | 0 (0.0) | 1 (2.0) | 1.0 |
MMF | 0 (0.0) | 6 (12.2) | 0.17 |
MZR | 3 (12.5) | 14 (28.6) | 0.15 |
AZA | 0 (0.0) | 2 (4.1) | 1.0 |
MTX | 3 (12.5) | 2 (4.1) | 0.32 |
SASP | 2 (8.3) | 0 (0.0) | 0.11 |
IGU | 0 (0.0) | 1 (2.0) | 1.0 |
BUC | 1 (4.2) | 0 (0.0) | 0.33 |
BEL/RTX/CY/PE/IVIg | 0 (0.0) | 0 (0.0) | NA |
Values are expressed as number (%) or median (IQR).
*Prednisolone equivalent (mg/day).
AZA, azathioprine; BEL, belimumab; BUC, bucillamine; CY, cyclophosphamide; CyA, ciclosporin; GC, glucocorticoid; HCQ, hydroxychloroquine; IGU, iguratimod; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; MTX, methotrexate; MZR, mizoribine; N/A, not applicable; PE, plasma exchange; RTX, rituximab; SASP, salazosulfapyridine; Tac, tacrolimus.